瑞香素调控Src/FAK通路对鼻咽癌细胞增殖、迁移和上皮间质转化的影响

doi:10.11958/20260416

天津医药 ›› 2026, Vol. 54 ›› Issue (8): 790-795.doi: 10.11958/20260416

瑞香素调控Src/FAK通路对鼻咽癌细胞增殖、迁移和上皮间质转化的影响

马月湘¹(), 冯展旺², 王千雨², 彭锦雯², 王文颖², 朱镇华¹, 宾骥¹^,^△()

¹ 湖南中医药大学第一附属医院耳鼻咽喉头颈外科（邮编410007）
² 湖南中医药大学研究生院

收稿日期:2026-02-05 修回日期:2026-03-24 出版日期:2026-08-15 发布日期:2026-08-07
通讯作者: △E-mail：494921383@qq.com
作者简介:马月湘（1990），女，主治医师，主要从事中西医结合防治耳鼻咽喉疾病方面研究。E-mail：mayuexiang8898@163.com
基金资助:
国家中医优势专科建设单位(国中医药医政函[2024]90号);湖南省中医耳鼻喉临床医学研究中心(2021SK4024)

The effects of daphnetin regulating the Src/FAK pathway on the proliferation, migration and epithelial-mesenchymal transition of nasopharyngeal carcinoma cells

MA Yuexiang¹(), FENG Zhanwang², WANG Qianyu², PENG Jinwen², WANG Wenying², ZHU Zhenhua¹, BIN Ji¹^,^△()

¹ Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha 410007, China
² Graduate School of Hunan University of Chinese Medicine

Received:2026-02-05 Revised:2026-03-24 Published:2026-08-15 Online:2026-08-07
Contact: △E-mail: 494921383@qq.com

马月湘, 冯展旺, 王千雨, 彭锦雯, 王文颖, 朱镇华, 宾骥. 瑞香素调控Src/FAK通路对鼻咽癌细胞增殖、迁移和上皮间质转化的影响[J]. 天津医药, 2026, 54(8): 790-795.

MA Yuexiang, FENG Zhanwang, WANG Qianyu, PENG Jinwen, WANG Wenying, ZHU Zhenhua, BIN Ji. The effects of daphnetin regulating the Src/FAK pathway on the proliferation, migration and epithelial-mesenchymal transition of nasopharyngeal carcinoma cells[J]. Tianjin Medical Journal, 2026, 54(8): 790-795.

摘要/Abstract

摘要：

目的探究瑞香素调控类固醇受体共激活因子（Src）/局部黏着斑激酶（FAK）通路对鼻咽癌细胞增殖、迁移和上皮间质转化的影响。方法将人鼻咽癌细胞5-8F分为对照组、L-瑞香素（4 mg/L）组、M-瑞香素（8 mg/L）组、H-瑞香素（12 mg/L）组、H-瑞香素+激活剂（3 μmol/L Src家族激活剂）组。细胞计数试剂盒8（CCK-8）和集落形成实验检测细胞增殖情况。流式细胞术检测凋亡。划痕愈合实验检测细胞迁移能力。Western blot检测上皮间质转化相关蛋白[E-钙黏蛋白（E-cadherin）、N-钙黏蛋白（N-cadherin）、波形蛋白（vimentin）]及Src和FAK蛋白表达。结果与对照组相比，L-瑞香素组、M-瑞香素组、H-瑞香素组5-8F细胞的光密度（OD）₄₅₀值降低，集落形成数减少，凋亡率升高，划痕愈合率降低，E-cadherin蛋白表达升高，N-cadherin和vimentin蛋白表达降低，p-Src和p-FAK蛋白表达降低（P<0.05），且不同质量浓度间差异有统计学意义（P<0.05）；与H-瑞香素组比较，H-瑞香素+激活剂组5-8F细胞的OD₄₅₀值升高，集落形成数增加，凋亡率降低，划痕愈合率升高，E-cadherin蛋白表达降低，N-cadherin和vimentin蛋白表达升高，p-Src和p-FAK1的蛋白表达升高（P<0.05）。结论瑞香素可通过抑制Src/FAK通路进而抑制鼻咽癌细胞的增殖、迁移和上皮间质转化。

关键词: 白瑞香素, 鼻咽癌, 基因, src, 黏着斑蛋白酪氨酸激酶类, 细胞增殖, 细胞运动, 上皮-间质转化

Abstract:

Objective To investigate the effects of daphnetin regulating the steroid receptor coactivator (Src)/focal adhesion kinase (FAK) pathway on the proliferation, migration and epithelial-mesenchymal transition of nasopharyngeal carcinoma cells. Methods Human nasopharyngeal carcinoma cells 5-8F were assigned into the control group, the L-daphnetin (4 mg/L) group, the M-daphnetin (8 mg/L) group, the H-daphnetin (12 mg/L) group and the H-daphnetin+activator (3 μmol/L Src-family activator) group. Cell proliferation was detected by cell counting kit 8 (CCK-8) and colony formation assay. Apoptosis was detected by flow cytometry. The cell migration ability was detected using the scratch healing test. Western blot assay was used to detect the expressions of epithelial-mesenchymal transition-related proteins (E-cadherin, N-cadherin, vimentin), Src and FAK proteins. Results Compared with the control group, the OD₄₅₀ values of 5-8F cells in the L-daphnetin group, the M-daphnetin group and the H-daphnetin group were lower, the number of colony formation was less, the apoptosis rate was higher, the scratch healing rate was lower, the expression of E-cadherin protein was higher, the expressions of N-cadherin and vimentin proteins were lower, and the protein expressions of p-Src and p-FAK were lower (P<0.05), and there were obvious differences between different concentrations (P<0.05). Compared with the H-daphnetin group, the OD₄₅₀ value of 5-8F cells in the H-daphnetin+activator group was higher, the number of colony formation was more, the apoptosis rate was lower, the scratch healing rate was higher, the expression of E-cadherin protein was lower, the expressions of N-cadherin and vimentin proteins were higher, and the protein expressions of p-Src and p-FAK were higher (P<0.05). Conclusion Daphnetin can inhibit the proliferation, migration and epithelial-mesenchymal transition of nasopharyngeal carcinoma cells by suppressing the Src/FAK pathway.

Key words: Daphnetin, nasopharyngeal carcinoma, genes, src, focal adhesion protein-tyrosine kinases, cell proliferation, cell movement, epithelial-mesenchymal transition

中图分类号:

R739.6

图/表 10

图1 Western blot检测各细胞系中p-Src和p-FAK的蛋白表达 A：NP69细胞；B：5-8F细胞；C：HNE1细胞；D：C666-1细胞；E：NPC/HK1细胞。

Fig.1 Western blot analysis of p-Src and p-FAK protein expression in various cell lines

表1 各细胞系中p-Src和p-FAK蛋白表达比较

Tab.1 Comparison of p-Src and p-FAK protein expression between various cell lines （n=6，$\bar{x}±s$）

细胞	p-Src/Src	p-FAK/FAK
NP69	0.32±0.05	0.27±0.04
5-8F	0.86±0.09^a	0.82±0.09^a
HNE1	0.74±0.08^a	0.68±0.08^ab
C666-1	0.57±0.07^ab	0.52±0.06^ab
NPC/HK1	0.78±0.09^a	0.70±0.06^ab
F	46.080^＊＊	52.356^＊＊

表2 各组5-8F细胞OD450值、集落形成数、凋亡率以及划痕愈合率比较

Tab.2 Comparison of OD450 values, colony-forming numbers, apoptosis rates and scratch healing rates between the five groups of 5-8F cells （n=6，$\bar{x}±s$）

组别	OD₄₅₀值	集落形成数/个
对照组	1.96±0.21	152.27±18.39
L-瑞香素组	1.64±0.19^a	126.38±15.87^a
M-瑞香素组	1.32±0.15^ab	99.64±11.92^ab
H-瑞香素组	1.01±0.12^abc	74.46±9.84^abc
H-瑞香素+激活剂组	1.89±0.20^d	148.64±17.16^d
F	30.330^＊＊	29.310^＊＊
组别	凋亡率/%	划痕愈合率/%
对照组	2.59±0.34	41.28±4.83
L-瑞香素组	9.85±1.18^a	33.73±3.96^a
M-瑞香素组	16.57±2.06^ab	26.32±3.21^ab
H-瑞香素组	23.64±2.84^abc	18.95±2.34^abc
H-瑞香素+激活剂组	4.76±0.62^d	39.67±4.65^d
F	158.761^＊＊	34.402^＊＊

图2 各组5-8F细胞集落形成测定

Fig.2 Determination of 5-8F cell colony formation in each group

图3 各组5-8F细胞凋亡情况

Fig.3 Apoptosis of 5-8F cells in each group

图4 各组5-8F细胞划痕愈合图像（×100）

Fig.4 Scratch healing images of 5-8F cells in each group (×100)

图5 Western blot检测5-8F中E-cadherin、N-cadherin和vimentin蛋白表达 A：对照组；B：L-瑞香素组；C：M-瑞香素组；D：H-瑞香素组；E：H-瑞香素+激活剂组。图6同。

Fig.5 Western blot detection of E-cadherin, N-cadherin and vimentin protein expression in 5-8F cells

表3 各组5-8F细胞中E-cadherin、N-cadherin和vimentin蛋白表达比较

Tab.3 Comparison of E-cadherin, N-cadherin and vimentin protein expression between five groups of 5-8F cells （n=6，$\bar{x}±s$）

组别	E-cadherin	N-cadherin	vimentin
对照组	1.01±0.11	1.06±0.11	1.07±0.12
L-瑞香素组	1.29±0.15^a	0.81±0.09^a	0.83±0.10^a
M-瑞香素组	1.56±0.17^ab	0.56±0.08^ab	0.59±0.07^ab
H-瑞香素组	1.89±0.20^abc	0.31±0.05^abc	0.35±0.05^abc
H-瑞香素+激活剂组	1.09±0.12^d	0.95±0.12^d	0.99±0.13^d
F	33.135^＊＊	63.566^＊＊	54.012^＊＊

图6 Western blot检测5-8F细胞中p-Src和p-FAK蛋白表达

Fig.6 Western blot detection of protein expression of p-Src and p-FAK in 5-8F cells

表4 各组5-8F细胞中p-Src和p-FAK蛋白表达比较

Tab.4 Comparison of p-Src and p-FAK protein expression between five groups of 5-8F cells （n=6，$\bar{x}±s$）

组别	p-Src/Src	p-FAK/FAK
对照组	0.86±0.11	0.78±0.09
L-瑞香素组	0.67±0.09^a	0.59±0.08^a
M-瑞香素组	0.49±0.07^ab	0.41±0.06^ab
H-瑞香素组	0.32±0.04^abc	0.23±0.04^abc
H-瑞香素+激活剂组	0.81±0.10^d	0.74±0.09^d
F	41.403^＊＊	57.356^＊＊

参考文献 21

[1]	Su Z Y, Siak P Y, Lwin Y Y, et al. Epidemiology of nasopharyngeal carcinoma:current insights and future outlook[J]. Cancer Metastasis Rev, 2024, 43(3):919-939. doi:10.1007/s10555-024-10176-9.
[2]	Huang H, Yao Y, Deng X, et al. Immunotherapy for nasopharyngeal carcinoma:current status and prospects (review)[J]. Int J Oncol, 2023, 63(2):97. doi:10.3892/ijo.2023.5545.
[3]	Wei X, Chen B, Wang Z, et al. Nasopharyngeal cancer risk assessment by country or region worldwide from 1990 to 2019[J]. BMC Public Health, 2024, 24(1):1931. doi:10.1186/s12889-024-19228-9.
[4]	Wei Z, Wei N, Su L, et al. The molecular effects underlying the pharmacological activities of daphnetin[J]. Front Pharmacol, 2024, 15:1407010. doi:10.3389/fphar.2024.1407010.
[5]	Pei Q, Hu P, Zhang H, et al. Daphnetin exerts an anticancer effect by attenuating the pro-inflammatory cytokines[J]. J Biochem Mol Toxicol, 2021, 35(6):1-8. doi:10.1002/jbt.22759.
[6]	Li T, Yang G, Hao Q, et al. Daphnetin ameliorates the expansion of chemically induced hepatocellular carcinoma via reduction of inflammation and oxidative stress[J]. J Oleo Sci, 2022, 71(4):575-585. doi:10.5650/jos.ess21415.
[7]	Li J, Zhang Z, Feng X, et al. Stanniocalcin-2 promotes cell EMT and glycolysis via activating ITGB2/FAK/SOX6 signaling pathway in nasopharyngeal carcinoma[J]. Cell Biol Toxicol, 2022, 38(2):259-272. doi:10.1007/s10565-021-09600-5.
[8]	Xiao L, Qijin P, Yimei L, et al. In silico analysis and experimental validation to exhibit anti-nasopharyngeal carcinoma effects of plumbagin,an anti-cancer compound[J]. J Sci Food Agric, 2022, 102(12):5460-5467. doi:10.1002/jsfa.11900.
[9]	Jie L, Lan H, Wenqing Z, et al. Evodiamine inhibits proliferation and induces apoptosis of nasopharyngeal carcinoma cells via the SRC/ERBB2-mediated MAPK/ERK signaling pathway[J]. J Transl Med, 2024, 22(1):859. doi:10.1186/s12967-024-05656-z.
[10]	Lv Z, Du Y, Zhang H, et al. Inhibition of JNK/STAT3/NF-KB pathway-mediated migration and clonal formation of lung adenocarcinoma A549 cells by daphnetin[J]. Cell Adh Migr, 2024, 18(1):27-37. doi:10.1080/19336918.2024.2418049.
[11]	韩江红, 王文翔, 罗欢欢, 等. 淫羊藿苷调控Src/FAK通路影响卵巢癌细胞顺铂耐药性的作用机制[J]. 中药新药与临床药理, 2025, 36(6):852-858.
	Han J H, Wang W X, Luo H H, et al. Mechanism of icariin regulating Src/FAK pathway affecting cisplatin resistance in ovarian cancer cells[J]. Chinese Journal of New Drugs and Clinical Pharmacology, 2025, 36(6):852-858. doi:10.19378/j.issn.1003-9783.2025.06.002.
[12]	朱文鹏, 韩梦琦, 王雨欣, 等. 1990—2019年中国鼻咽癌发病与死亡的趋势及预测研究[J]. 中国全科医学, 2023, 26(34):4269-4276.
	Zhu W P, Han M Q, Wang Y X, et al. Trends and predictions of incidence and mortality of nasopharyngeal carcinoma in China from 1990 to 2019[J]. Chinese General Practice, 2023, 26(34):4269-4276. doi:10.12114/j.issn.1007-9572.2023.0247.
[13]	黄丽珍, 龙泉先, 李国余, 等. 卡瑞利珠单抗联合卡培他滨用于一线治疗复发转移鼻咽癌患者维持治疗疗效及对患者免疫功能的影响[J]. 现代生物医学进展, 2024, 24(4):724-728.
	Huang L Z, Long Q X, Li G Y, et al. Effect of carelizumab combined with capecitabine on maintenance therapy efficacy and immune function in first-line treatment of patients with recurrent metastatic nasopharyngeal carcinoma[J]. Advances in Modern Biomedicine, 2024, 24(4):724-728. doi:10.13241/j.cnki.pmb.2024.04.024.
[14]	Deng Q, Wu L, Li Y, et al. Chemoprotective effect of daphnetin in doxorubicin treated esophageal cancer stem cell xenograft tumor mouse[J]. Dokl Biochem Biophys, 2021, 499(1):273-281. doi:10.1134/S1607672921040128.
[15]	Liu C, Pan J, Liu H, et al. Daphnetin inhibits the survival of hepatocellular carcinoma cells through regulating Wnt/β-catenin signaling pathway[J]. Drug Dev Res, 2022, 83(4):952-960. doi:10.1002/ddr.21920.
[16]	Gong S, Liu H, Wu J, et al. Effects of daphnetin on the mechanism of epithelial-mesenchymal transition induced by HMGB1 in human lung adenocarcinoma cells (A549 cell line)[J]. Biotechnol Genet Eng Rev, 2024, 40(3):1489-1510. doi:10.1080/02648725.2023.2194092.
[17]	Fan X, Xie M, Zhao F, et al. Daphnetin triggers ROS-induced cell death and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway in ovarian cancer[J]. Phytomedicine, 2021, 82:153465. doi:10.1016/j.phymed.2021.153465.
[18]	Katoh K. Focal adhesion kinase (FAK) and c-Src dependent signal transduction in cell adhesion[J]. Discov Med, 2024, 36(189):1998-2012. doi:10.24976/Discov.Med.202436189.184.
[19]	Raji L, Tetteh A, Amin A R M R. Role of c-Src in carcinogenesis and drug resistance[J]. Cancers (Basel), 2023, 16(1):32. doi:10.3390/cancers16010032.
[20]	Huang Y H, Chen H K, Hsu Y F, et al. Src-FAK signaling mediates interleukin 6-induced HCT116 colorectal cancer epithelial-mesenchymal transition[J]. Int J Mol Sci, 2023, 24(7):6650. doi:10.3390/ijms24076650.
[21]	Pan R, Yu Y, Zhu H, et al. RSPO2 promotes progression of ovarian cancer through dual receptor-mediated FAK/Src signaling activation[J]. iScience, 2022, 25(10):105184. doi:10.1016/j.isci.2022.105184.

瑞香素调控Src/FAK通路对鼻咽癌细胞增殖、迁移和上皮间质转化的影响

The effects of daphnetin regulating the Src/FAK pathway on the proliferation, migration and epithelial-mesenchymal transition of nasopharyngeal carcinoma cells

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 10

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张渤, 徐伟, 张静, 马肖. GFPT1通过调节PD-L1通路对非小细胞肺癌细胞的影响[J]. 天津医药, 2026, 54(7): 687-692.
[2]	张轶轶, 刘帝亮, 陈飞, 龚媛媛, 王贵生. MTA1、ARL2和VEGF-C在非小细胞肺癌组织中的表达[J]. 天津医药, 2026, 54(7): 705-710.
[3]	董倩, 陈淑华, 张飞. ACE2在结直肠癌耐药中的作用及其预测价值的研究[J]. 天津医药, 2026, 54(6): 561-569.
[4]	卢红霞, 郭燕军, 黄晗, 张婷. miR-421靶向MPP7/EGFR/AKT轴影响巨噬细胞M2极化改善哮喘小鼠的气道炎症[J]. 天津医药, 2026, 54(5): 462-468.
[5]	刘瑢, 项艳曾, 马丽娟, 张鹏. 腺病毒介导的SPRY1过表达对肝细胞癌凋亡和自噬的影响[J]. 天津医药, 2026, 54(4): 337-343.
[6]	钱永, 陈沐秀, 郑爽. COX-2在口腔鳞状细胞癌增殖与侵袭中的作用研究[J]. 天津医药, 2026, 54(4): 352-357.
[7]	刘家妮, 苏帅, 张爱婷, 徐昕, 王邦茂. 霍乱毒素抗肿瘤作用的研究进展[J]. 天津医药, 2026, 54(4): 438-443.
[8]	杨晓芳, 贾新燕, 丰文君. miR-181a-5p通过HMGB1/NF-κB信号通路调控狼疮性肾炎小鼠肾小球系膜细胞增殖和凋亡[J]. 天津医药, 2026, 54(3): 232-237.
[9]	王丹, 金卓婷, 潘长清, 郑茜文, 于文亮, 邓艳梅, 张勇. 绵阳地区育龄女性FMR1和SMN1基因与耳聋相关基因筛查情况分析[J]. 天津医药, 2026, 54(3): 329-332.
[10]	黄熷远, 付靖, 赵亚, 王龙灏, 仓顺东. 非小细胞肺癌EGFR-TKI耐药与p53基因突变的研究进展[J]. 天津医药, 2026, 54(3): 333-336.
[11]	吴蝶, 丁利军. 氨基酸代谢调控卵巢衰老研究新进展[J]. 天津医药, 2026, 54(2): 139-144.
[12]	王喆, 邱林, 马贲. 番茄来源胞外囊泡样颗粒对口腔鳞状细胞癌的作用效果研究[J]. 天津医药, 2026, 54(2): 145-150.
[13]	赵兰君, 李良惠, 马馨, 巩娇娇, 郑臣辉, 石琳. 穿心莲内酯调控STAT3/GPX4通路对骨髓瘤细胞增殖和凋亡的影响[J]. 天津医药, 2026, 54(1): 8-13.
[14]	杨桃, 全艳, 张加孟, 谢清耘, 黄麟洲. 甲状腺结节细针穿刺细胞学联合BRAF基因检测在甲状腺良恶性肿瘤鉴别诊断中的应用价值[J]. 天津医药, 2025, 53(9): 972-975.
[15]	刘虹, 张玥玥, 王一琳, 王彩丽, 王晓敏, 毛敏, 李燕. MicroRNA-34a通过调控Wnt途径影响慢性淋巴细胞白血病进展的机制探讨[J]. 天津医药, 2025, 53(8): 785-790.